Induced PKU in rats: effects of age and melatonin treatment

Area of Science:

• Neuroscience
• Biochemistry
• Developmental Biology

Background:

• Phenylketonuria (PKU) is a human genetic disorder.
• PKU leads to phenylalanine buildup and neurological issues.
• Animal models are crucial for studying PKU and developing treatments.

Purpose of the Study:

• To investigate the impact of early-life L-phenylalanine and p-chlorophenylalanine administration on rat development.
• To assess the resulting biochemical and behavioral changes, particularly maze learning.
• To evaluate the potential therapeutic effect of melatonin on these induced symptoms.

Main Methods:

• Newborn rats were injected with L-phenylalanine (2 g/kg) and p-chlorophenylalanine (80 mg/kg) during specific early life periods (Days 1-8, 9-16, or 7-24).
• Biochemical markers analogous to human PKU were monitored.
• Maze learning tasks were used to assess behavioral impairments.
• Melatonin (10 mg/kg/day) was co-administered in some groups.

Main Results:

• Rats treated during Days 1-8 exhibited biochemical PKU-like symptoms and significant maze learning impairments.
• Later treatment periods (Days 9-16 and 7-24) resulted in less pronounced behavioral effects.
• Co-administration of melatonin did not alleviate the observed biochemical or behavioral symptoms.

Conclusions:

• Early-life exposure to specific amino acid derivatives can induce PKU-like conditions and cognitive deficits in rats.
• The timing of exposure is critical, with early developmental stages being most vulnerable.
• Melatonin is not an effective treatment for these experimentally induced PKU symptoms in rats.